Ianalumab

Ianalumab (INN;[1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis.

Ianalumab
Monoclonal antibody
Type?
SourceHuman
TargetBAFF receptor
Clinical data
Other namesVAY736
ATC code
  • none
Identifiers
CAS Number
UNII

This drug is being developed by Novartis. As of 2018, ianalumab is undergoing Phase II/III trials.

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.